Prof Kenneth O'Byrne

Prof Kenneth O'Byrne is a highly esteemed Medical Oncologist and Clinical Scientist who has made significant contributions to the field of thoracic oncology throughout his illustrious 30-year career. Renowned for his expertise, he is the founder of the British Thoracic Oncology Group (BTOG) and the European thoracic oncology platform (ETOP).

Prof O'Byrne’s influence extends to various educational and fellowship committees, including the International Association for the Study of Lung Cancer (IASLC) and the Thoracic Alliance for Cancer Trials (TACT). With an unwavering commitment to advancing the field, he actively participates in more than 200 clinical trials, seamlessly designing and implementing Phase II and III studies.

Key to Prof O'Byrne's acclaim is his international leadership in biomarker research. He has been instrumental in establishing collaborative studies and networks for both biomarker detection and validation. His expertise in this area is exemplified through his involvement in groundbreaking biomarker-driven clinical trials, such as the LUX-Lung, checkpoint immunotherapy, and ETOP programs.

Presently, Prof O'Byrne holds the position of Clinical Lead for the Cancer and Ageing Research Program at the Queensland University of Technology Translational Research Institute laboratories. In his research, he actively investigates biomarkers within solid and liquid biopsies, explores drug resistance mechanisms associated with cancer 'stemness', and delves into genomic instability. This work involves collaborations with scientists worldwide, with ongoing projects focusing on drug resistance, DNA repair and genomic instability, and whole genome sequencing, in partnership with various groups in Europe and the United States.

Prof O'Byrne has an extensive publication record, boasting over 300 peer-reviewed papers that showcase his authoritative contributions to the field. Notably, he has patented novel anti-cancer therapeutics and predictive biomarker tests in Australia and Ireland. Funding for his groundbreaking research has been secured from prestigious bodies such as the National Health and Medical Research Council (NHMRC), Cancer Council Australia, Cancer Council Qld, and the National Breast Cancer Foundation.

In summary, Prof Kenneth O'Byrne's profound impact in thoracic oncology, along with his pivotal role in advancing biomarker detection and validation, have established him as a highly respected and influential researcher in his field.